Olpasiran for Preventing Cardiovascular Events in Elevated Lipoprotein(a)

This clinical trial is focused on finding out if a drug called olpasiran can help prevent serious heart problems in people with high levels of a specific substance in their blood known as lipoprotein(a). People with elevated lipoprotein(a) are more at risk of heart disease, including deaths caused by coronary heart disease, heart attacks, or the need for urgent heart procedures. The goal is to see if olpasiran can lower these risks compared to a placebo, which is a substance with no active drug. Participants in the study will receive either the olpasiran drug or a placebo. The study is conducted in a way that neither the participants nor the researchers know who is receiving the actual drug or the placebo, which helps ensure unbiased results. The researchers will measure the effectiveness by keeping track of occurrences of heart-related events in the participants. The potential benefits include reducing the risk of major cardiovascular events for those with high lipoprotein(a), although like any clinical trial, there could be risks or side effects that will be monitored closely.